Key result
A 44-year-old woman developed a hemorrhagic pericardial effusion with tamponade physiology three weeks after a COVID-19 diagnosis, which improved after a pericardial window and colchicine therapy.
Case Report (n=1)
No
Hemorrhagic pericardial effusion with tamponade physiology is a rare but potentially lethal late manifestation of COVID-19 infection that can be managed with a pericardial window and colchicine.
Answers are grounded in this paper and cite their sources.
Hemorrhagic tamponade may occur weeks after COVID-19; hypothesis-generating and should not change practice.
A 44-year-old woman with a history of factor V Leiden deficiency and recurrent pulmonary emboli was diagnosed with coronavirus disease 2019 (COVID-19) three weeks prior presented to her local ED with severe chest pain. She was found to have a large hemorrhagic pericardial effusion by cardiac MRI with echocardiographic signs of tamponade. She underwent the creation of a pericardial window and was treated with colchicine with improvement in symptoms.
No takes yet. Share an insight, caveat, or question.
Foster et al. (2021) conducted a case report in Hemorrhagic Pericardial Effusion with Tamponade Physiology (n=1). Pericardial window and colchicine was evaluated on Symptom improvement. A 44-year-old woman developed a hemorrhagic pericardial effusion with tamponade physiology three weeks after a COVID-19 diagnosis, which improved after a pericardial window and colchicine therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: